Drug combinations in malignant NK-cell lines. (A) Differential DSS (dDSS) values comparing the response to compounds in the presence vs absence of 300 nM ruxolitinib. ZIP scores represent the drug synergies based on viability (B) and cytotoxicity (C) readout. Each dot represents a different cell line; the bar represents the variability between cell lines, and the line represents the median of TP53-mutant (orange) and STAT3-mutant (teal) NK-cell lines. Drug combination matrices in viability and toxicity readouts with ruxolitinib and idasanutlin or tipifarnib in TP53-mutant NK-92 cell line (D) and STAT3-mutant YT cell line (E) are shown. Assays were conducted in single wells normalized plate-wise to negative (DMSO) and positive (BzCl) controls. dDSS values were calculated by subtracting the DSS(DMSO) from the DSS(ruxo). DSS values are provided in supplemental Data 1, and drug combination matrix figures for all tested cell lines and drugs are provided in supplemental Data 2.